321 related articles for article (PubMed ID: 12860940)
21. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
22. Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome.
Romine PE; Martins RG; Eaton KD; Wood DE; Behnia F; Goulart BHL; Mulligan MS; Wallace SG; Kell E; Bauman JE; Patel SA; Vesselle HJ
BMC Cancer; 2019 Jan; 19(1):70. PubMed ID: 30642285
[TBL] [Abstract][Full Text] [Related]
23. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Langen HJ; Bares R
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
[TBL] [Abstract][Full Text] [Related]
24. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Tiseo M; Ippolito M; Scarlattei M; Spadaro P; Cosentino S; Latteri F; Ruffini L; Bartolotti M; Bortesi B; Fumarola C; Caffarra C; Cavazzoni A; Alfieri RR; Petronini PG; Bordonaro R; Bruzzi P; Ardizzoni A; Soto Parra HJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):299-307. PubMed ID: 24258456
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
[TBL] [Abstract][Full Text] [Related]
26. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma.
Cerfolio RJ; Ojha B; Mukherjee S; Pask AH; Bass CS; Katholi CR
J Thorac Cardiovasc Surg; 2003 Apr; 125(4):938-44. PubMed ID: 12698159
[TBL] [Abstract][Full Text] [Related]
27. Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.
Chaft JE; Dunphy M; Naidoo J; Travis WD; Hellmann M; Woo K; Downey R; Rusch V; Ginsberg MS; Azzoli CG; Kris MG
J Thorac Oncol; 2016 Apr; 11(4):537-44. PubMed ID: 26724474
[TBL] [Abstract][Full Text] [Related]
28. Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer.
Banna GL; Anile G; Russo G; Vigneri P; Castaing M; Nicolosi M; Strano S; Gieri S; Spina R; Patanè D; Calcara G; Fraggetta F; Marletta F; Stefano A; Ippolito M
Oncology; 2017; 92(1):39-47. PubMed ID: 27832654
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic value of (18)F-fluorodeoxyglucose uptake in patients with non-small cell lung cancer treated by concurrent chemoradiotherapy].
Zhang HQ; Yu JM; Meng X; Yue JB; Feng R; Ma L
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):603-6. PubMed ID: 21122413
[TBL] [Abstract][Full Text] [Related]
30. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Kahraman D; Holstein A; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Dietlein M; Wolf J; Kobe C
Clin Nucl Med; 2012 Nov; 37(11):1058-64. PubMed ID: 23027207
[TBL] [Abstract][Full Text] [Related]
31. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer.
Tanvetyanon T; Eikman EA; Sommers E; Robinson L; Boulware D; Bepler G
J Clin Oncol; 2008 Oct; 26(28):4610-6. PubMed ID: 18824709
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy.
Kaira K; Yamamoto N; Kenmotsu H; Murakami H; Ono A; Naito T; Endo M; Takahashi T
Respir Investig; 2014 Mar; 52(2):121-8. PubMed ID: 24636268
[TBL] [Abstract][Full Text] [Related]
34. [Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment].
Schmücking M; Baum RP; Bonnet R; Junker K; Müller KM
Pathologe; 2005 May; 26(3):178-89. PubMed ID: 15800765
[TBL] [Abstract][Full Text] [Related]
35. Early detection of disease progression after palliative chemotherapy in NSCLC patients by (18)F-FDG-PET.
Tauhardt E; Reissig A; Winkens T; Freesmeyer M
Nuklearmedizin; 2014; 53(5):197-204. PubMed ID: 24986272
[TBL] [Abstract][Full Text] [Related]
36. Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in non-small-cell lung cancer.
Sharma A; Mohan A; Bhalla AS; Vishnubhatla S; Pandey AK; Bal CS; Kumar R
Nucl Med Commun; 2017 Oct; 38(10):858-867. PubMed ID: 28817456
[TBL] [Abstract][Full Text] [Related]
37. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S
Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
[TBL] [Abstract][Full Text] [Related]
38. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE
Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556
[TBL] [Abstract][Full Text] [Related]
39. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
[TBL] [Abstract][Full Text] [Related]
40. The Predictive Value of Early In-Treatment
Usmanij EA; Natroshvili T; Timmer-Bonte JNH; Oyen WJG; van der Drift MA; Bussink J; Geus-Oei LF
J Nucl Med; 2017 Aug; 58(8):1243-1248. PubMed ID: 28336778
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]